2.9 C
Glasgow
Sunday, December 21, 2025
spot_img

More News

First precision therapy prostate cancer drug approved

Jim Cornall -
Johnson & Johnson says the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)...

FDA approves generalised myasthenia gravis drug

Jim Cornall -
Amgen says the U.S. Food and Drug Administration (FDA) has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalised myasthenia...

Breast cancer vaccine endpoints met with 74% immune response

Jim Cornall -
Anixa Biosciences, Inc. has announced the presentation of final data from the phase 1 clinical trial of its investigational...

Lilly to build $6bn Alabama facility

Jim Cornall -
Eli Lilly and Company has announced plans to invest more than $6bn in a new manufacturing facility in Huntsville,...

PsiThera unveiled with $47.5m funding to advance oral medicines

Jim Cornall -
PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained...

Rapid diagnostic breakthrough against Klebsiella

Jim Cornall -
Antibiotic resistance is one of the most pressing—and quietly advancing—challenges facing modern medicine. Among the most dangerous bacterial pathogens...

Pan Cancer T raises €10m for first-in-human trial of novel TCR-T cell therapy for triple-negative breast cancer

Jim Cornall -
Pan Cancer T B.V., a biotech company pioneering next-generation T cell therapies for solid tumours, has announced a €10m...

Vivacta Bio shows promising results for in vivo CAR-T therapy in non-Hodgkin’s lymphoma

Jim Cornall -
Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, has...

OTR Therapeutics raises $100m for global transformative therapies

Jim Cornall -
OTR Therapeutics has emerged from stealth and announced the successful completion of a $100m Series A financing. The round was...

Base to Base biotech podcast 39: Gene therapy for eye problems, GAIA, and separation science

Jim Cornall -
This week, we have conversations with Jakob Andersson, vice president of engineering at Anaphora and founder and chairman of...

Endpoints not met, but data provides insights to Alzheimer’s pathobiology

Jim Cornall -
Novo Nordisk has presented new topline results from its Evoke and Evoke+ phase 3 trials of semaglutide, an oral...

CRS programme to feature Poolbeg Pharma trial

Jim Cornall -
Poolbeg Pharma’s POLB 001 TOPICAL trial is to feature in a cancer immunotherapy-induced cytokine release syndrome (CRS) research programme. Poolbeg...

ChemLex raises $45m and launches lab for drug discovery in Singapore

Jim Cornall -
ChemLex has announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a...

Potent and selective antitumour activity in acute myeloid leukaemia study

Jim Cornall -
Orum Therapeutics, a public biotechnology company working on degrader-antibody conjugates (DACs), has presented preclinical data for ORM-1153 at the...

Positive results from male and female infertility monoclonal antibody trial

Jim Cornall -
French infertility treatment biotech company Igyxos Biotherapeutics has announced the successful completion of its phase 1 clinical trial evaluation...

Positive results from ALS study

Jim Cornall -
AL-S Pharma has presented phase 2 clinical study results on AP-101 to treat amyotrophic lateral sclerosis (ALS) at the...

EspeRare receives Gates Foundation grant to advance preeclampsia novel therapy

Jim Cornall -
EspeRare, a Geneva-based nonprofit biotech, has been awarded a Grand Challenges grant from the Gates Foundation to strengthen its...

CRO Avetra launched

Jim Cornall -
Contract research organization (CRO) Avetra has officially launched with the aim of introducing a site-centric operating model to realign...

7,920 acre next-gen industry facility IBTEC launched in Malaysia

Jim Cornall -
JLand Group (JLG), the real estate and infrastructure arm of Johor Corporation (JCorp) in Malaysia, has launched Ibrahim Technopolis...

Oncoinvent publishes phase 1 ovarian cancer results

Jim Cornall -
Oncoinvent, a clinical stage, radiopharmaceutical company developing treatments for solid cancers, has announced the publication of 12-month data from...

Lower doses of immunotherapy for skin cancer give better results

Jim Cornall -
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours,...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media